Jubilant Ingrevia Limited (NSE:JUBLINGREA) announced the board approval of unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 on 22 July 2026. The consolidated net profit for Q1 FY27 stood at Rs 105.8 crore against Rs 85.2 crore in Q1 FY26, representing a 24.2% year-on-year increase. Consolidated revenue from operations rose to Rs 1,300.3 crore in Q1 FY27 from Rs 1,037.9 crore in the corresponding quarter last year, an increase of 25.3%. The board meeting was held from 11:00 a.m. to 12:25 p.m. on 22 July 2026.
Key Highlights
- Consolidated net profit for Q1 FY27 increased to Rs 105.8 crore, up 24.2% year-on-year from Rs 85.2 crore in Q1 FY26, as approved by the board on 22 July 2026.
- Consolidated revenue from operations rose to Rs 1,300.3 crore in Q1 FY27 from Rs 1,037.9 crore in Q1 FY26, reflecting a 25.3% year-on-year growth.
- Profit before tax for the consolidated quarter ended 30 June 2026 was Rs 140.9 crore, up from Rs 99.8 crore in Q1 FY26, an increase of 41.2%.
- Earnings per share on a basic and diluted basis for Q1 FY27 were Rs 6.70 and Rs 6.68 respectively, compared to Rs 4.75 in Q1 FY26.
- The company operates through three segments: Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates, with segment-wise revenue and profitability disclosed in the unaudited financial statement.
- The unaudited financial results were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and reviewed by statutory auditor Walker Chandiok & Co LLP under Regulation 33 of the SEBI Listing Regulations.
About the Company
Jubilant Ingrevia Limited (NSE:JUBLINGREA) is a specialty chemicals and pharmaceutical company headquartered at Bhartiagram, Gajraula, Uttar Pradesh. The company operates through three primary segments: Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. Jubilant Ingrevia manufactures and supplies active pharmaceutical ingredients (APIs), specialty chemicals, nutrition solutions, and chemical intermediates to domestic and international markets. The company is listed on the National Stock Exchange of India (NSE) with scrip code 543271 on BSE. Its operations span multiple manufacturing facilities and it maintains subsidiary companies across geographies including the United States, Netherlands, and China, as well as associate partnerships in renewable energy and food sectors.
Announcement in Detail
Jubilant Ingrevia's board of directors, in a meeting held on 22 July 2026 from 11:00 a.m. to 12:25 p.m., approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. This approval was made pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company simultaneously filed a copy of the financial results and the limited review report issued by statutory auditor Walker Chandiok & Co LLP under Regulation 33 of the Listing Regulations. Both documents were made available on the company's website at www.jubilantingrevia.com.
For the consolidated quarter ended 30 June 2026, the company reported total income (revenue from operations plus other income) of Rs 1,310.5 crore. Total consolidated expenses stood at Rs 1,169.6 crore, resulting in a profit before the share of loss of an associate and exceptional items of Rs 140.9 crore. After accounting for the share of loss of an associate of Rs 3 lakhs and exceptional items, the profit before tax was Rs 140.9 crore. Tax expense, comprising current tax of Rs 42.96 crore and deferred tax credit of Rs 7.92 crore, resulted in a net profit attributable to owners of the company of Rs 105.8 crore. Total comprehensive income for the period was Rs 110.6 crore. The unaudited financial results were reviewed by Walker Chandiok & Co LLP, which confirmed that nothing came to their attention suggesting the Statement had not disclosed the required information in compliance with Regulation 33 of the Listing Regulations.
Impact on Investors
Investors will note that Jubilant Ingrevia's financial performance for Q1 FY27 demonstrates operational growth across key metrics. The 24.2% year-on-year increase in consolidated net profit to Rs 105.8 crore and the 25.3% rise in consolidated revenue from operations to Rs 1,300.3 crore indicate improved business performance. The profit before tax margin expanded to 10.76% in Q1 FY27 from 9.52% in Q1 FY26, suggesting improved operational efficiency and cost management. Earnings per share (basic) of Rs 6.70 in Q1 FY27 represents a 41.1% increase compared to Rs 4.75 in Q1 FY26, reflecting stronger profitability on a per-share basis.
The filing shows the company operates through diversified business segments. Segment-wise profitability for Q1 FY27 indicates Speciality Chemicals contributed Rs 109.1 crore to profit before tax and interest, Nutrition & Health Solutions contributed Rs 28.3 crore, and Chemical Intermediates contributed Rs 44.0 crore. The company also maintains subsidiary operations and associate interests, with the consolidated statement incorporating the financial information of eight subsidiary entities and three associate entities. The limited review conducted by the statutory auditors did not identify any material misstatements, indicating the financial results are prepared in accordance with applicable accounting standards and disclosure requirements.
Sector / Market Context
Jubilant Ingrevia operates within India's specialty chemicals and pharmaceutical intermediates sector, which supplies critical inputs to both domestic pharmaceutical manufacturers and global chemical companies. The specialty chemicals segment serves multiple end-user industries including pharmaceuticals, agrochemicals, and fine chemicals. India's pharmaceutical sector, which relies substantially on domestic API and intermediate suppliers, has benefited from global supply chain diversification, as international companies seek alternatives to concentrated sourcing regions. The Nutrition & Health Solutions segment positions the company within India's growing functional nutrition and dietary supplement market, which has expanded due to increased domestic health consciousness and rising disposable incomes. Chemical Intermediates remain a core segment, serving as building blocks for pharmaceutical and specialty chemical synthesis. The company's multi-segment and multi-geography presence reflects the sector's capital-intensive nature and the importance of operational scale and technology capability for competitive positioning.